Genmab — April 2017
-
1.240 var et stærkt gulv. Vil tro at flere i A/B gruppen har timet efter det niveau.
-
Er det det modelstudie som dannede baggrund for CARINA?
-
Sorry..Det er det selvfølgelig ikke.
-
Med mindre mono trods alt var godt nok at starte på.
-
Det er i hvert konklusionen som jeg ikke kunne læse på mobilen.
-
Thanks E L. That sounds reasonable. We have previously talked about how data from dara should be
very good to get near Roche -
If not, it is better to close down.
-
This does not exclude other approaches to Dara in NHL.
-
@E L. Janssen do not have ownership in CD3-CD20. It is solely Genmab owned. Therefore Janssen would not know how good it is.
-
Jeg har fået en præcisering fra Rachel: Igangværende studier uden for MM ses på oversigten i seneste investorpræsentation April 2017. Janssen har ikke ændret deres planlægning for andre studier. Beslutning i torsdags var udelukkende Carina (mono for 3 NHL sygdomme). Der er studier i gang i andre ikke MM sygdomme, feks NKT Cell og amyloidosis og det betyder ikke at fremtidig der blive startet andre kombi studier, og så kommer de på oversigten også på dette tidspunkt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind